From classified Soviet labs to global longevity clinics
In the early 1970s, the Soviet military gave Vladimir Khavinson, a colonel in the KGB medical corps, a specific mandate: find ways to protect military personnel, cosmonauts, and athletes from the physiological stresses of modern warfare, space travel, and high-performance sport — particularly radiation exposure and rapid ageing under extreme conditions. Working at the St. Petersburg Institute of Bioregulation and Gerontology, Khavinson and his team discovered that short-chain peptides extracted from specific animal organs had remarkable tissue-specific regenerative effects. This research was classified for decades.
The core insight was that every organ produces short regulatory peptides — 2-4 amino acids long — that regulate gene expression in that specific tissue. These "bioregulators" interact directly with DNA through complementary binding, activating genes whose expression has been suppressed by ageing, stress, or disease. The mechanism is epigenetic: not genetic modification, but the restoration of gene expression patterns that decline with age.
After the Soviet Union's collapse in 1991, the research was declassified. Khavinson continued publishing until his death in 2024, accumulating 775 scientific publications and 196 patents. Six peptide-based pharmaceuticals and 64 food supplements were introduced into Russian clinical practice. The research claimed mortality reductions of up to four-fold in human subjects treated with bioregulator protocols — claims that remain extraordinary and require independent replication but are backed by decades of institutionally-conducted research.
The complete family: Cartalax (joints — already in this book), Thymulin (immune/thymus — already in this book), Pinealon (brain/pineal — already in this book), Epitalon (longevity/pineal — already in this book), and Cortagen (brain/cortex) are covered separately. This entry focuses on the organ-specific cardiovascular, hepatic, pulmonary, and metabolic bioregulators.
Gene expression regulation — the DNA interaction model
Shared Mechanism: Khavinson's Model
The organ-specific family
Cardiogen (Ala-Glu-Asp · P6): Cardiac tissue bioregulator. Targets gene expression in cardiomyocytes to support contractile function, reduce oxidative damage, and promote cellular repair. Clinical trial data in Russia shows reduced ischaemic heart disease incidence in treated patients vs controls.
Bronchogen (Ala-Asp-Glu-Leu): Lung and bronchial bioregulator. The Monaselidze study showed Bronchogen affects DNA thermostability — suggesting direct chromatin/gene interaction. Used for pulmonary support and respiratory tissue protection.
Livagen (Lys-Glu-Asp-Ala): Liver bioregulator with demonstrated chromatin remodelling effects. Timofeeva et al. showed Livagen affects digestive enzyme activity in rats across different ages. Khavinson's landmark study showed Livagen reactivated chromatin in lymphocytes from elderly subjects — one of the most compelling direct demonstrations of the epigenetic bioregulator mechanism.
Ovagen (Glu-Asp-Leu): Liver and stomach bioregulator. Pancragen (Lys-Glu-Asp): pancreatic bioregulator for insulin secretion and pancreatic tissue support. Prostamax (Lys-Glu-Asp-Ala): prostate gland bioregulator. Chonluten (Gly-Glu-Pro): bronchial/respiratory mucosal support.
Evidence caveat: The vast majority of Khavinson bioregulator research originates from the St. Petersburg Institute of Bioregulation and Gerontology — a single institution. Independent replication by Western research groups is limited. The claims are bold, the publications are numerous, and the mechanism is theoretically plausible — but the gold standard of independent multi-centre RCTs does not exist for most of these peptides outside Russia.
What people report
"I use the Khavinson protocol — pineal, thymic, circulatory as the base, then Livagen and Cardiogen added for my specific concerns. I've done this twice yearly for 3 years. Genuinely hard to attribute anything specific. But I feel meaningfully better than I did before I started, and my bloodwork has been consistently stable."
Male, 67. The combination protocol — using 4-5 bioregulators together in cycles, 2× yearly — is the approach Khavinson himself recommended and studied. The combination creates overlapping gene expression support that is more complete than any single bioregulator. Attribution is nearly impossible in a general wellness context.
"The Russian clinical data for Cardiogen specifically is actually quite compelling — reductions in cardiac event incidence that are hard to dismiss. It's not Western RCT data, but it's not nothing. I use them selectively in older patients who are already managing cardiovascular risk factors."
Integrative medicine physician. The Cardiogen and circulatory bioregulator clinical data is the strongest within the family — Russian clinical trials with mortality endpoint data. The evidence quality is lower than Western RCT standards but the findings are not implausible given the mechanism.
What the data shows
How to cycle bioregulators correctly
Khavinson's own protocol was never single-peptide — it was always combinatorial, targeting multiple organ systems simultaneously, cycled 1-2× yearly rather than used continuously.
Editor's summary
The Khavinson bioregulators sit in a genuinely unusual position in the evidence landscape: not the speculative animal-only research of most longevity peptides, but not the independent multi-centre RCT evidence of FDA-approved drugs either. The mechanism is theoretically compelling (epigenetic DNA interaction, confirmed chromatin remodelling), the publication volume is extraordinary (775 papers), and the Russian clinical outcomes data — while not by Western RCT standards — shows consistent patterns across decades of institutional practice. Khavinson was nominated for a Nobel Prize. His research was taken seriously enough to be classified for decades.
The honest limitation: virtually all evidence comes from a single institution. Independent replication is limited. The "four-fold mortality reduction" claims require extraordinary evidence that hasn't been independently reproduced. The mechanism, while plausible, is not yet accepted by mainstream Western pharmacology. Epitalon, Thymulin, Cartalax, and Pinealon (all in this book) are the members of this family with the most accessible evidence bases.
For people already engaged with longevity biology who want to explore a systematically developed, non-toxic, non-hormonal approach to organ-level maintenance, the Khavinson protocol is one of the most thoughtfully constructed systems available — it is just Russian rather than FDA-approved.